Genetics and variable drug response.
作者信息
Wilke Russell A, Dolan M Eileen
机构信息
Department of Medicine, Division of General Internal Medicine, and Oates Institute for Experimental Therapeutics, Vanderbilt University, Nashville, Tennessee 37232, USA.
出版信息
JAMA. 2011 Jul 20;306(3):306-7. doi: 10.1001/jama.2011.998.
Abstract
摘要
相似文献
1
Genetics and variable drug response.遗传学与药物反应的变异性
JAMA. 2011 Jul 20;306(3):306-7. doi: 10.1001/jama.2011.998.
2
Pharmacogenetics: The right drug for you.药物遗传学：适合你的正确药物。
Nature. 2016 Sep 8;537(7619):S60-2. doi: 10.1038/537S60a.
3
The promises of personalized medicine.个性化医疗的前景。
Eur J Clin Pharmacol. 2010 Aug;66(8):749-54. doi: 10.1007/s00228-010-0858-6. Epub 2010 Jun 19.
4
Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade.药物不良反应背景下的药物基因组学与全球精准医学：未来十年的十大机遇与挑战
OMICS. 2016 Oct;20(10):593-603. doi: 10.1089/omi.2016.0122. Epub 2016 Sep 19.
5
Facilitating clinical implementation of pharmacogenomics.促进药物基因组学的临床应用。
JAMA. 2011 Jul 20;306(3):304-5. doi: 10.1001/jama.2011.1010.
6
Pharmacogenomic considerations for medications in the perioperative setting.围手术期药物的药物基因组学考虑因素。
Pharmacogenomics. 2019 Jul;20(11):813-827. doi: 10.2217/pgs-2019-0040.
7
Pharmacogenetics: Chasing Perfection.药物遗传学：追求完美。
Clin Pharmacol Ther. 2019 Aug;106(2):265-270. doi: 10.1002/cpt.1511.
8
Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine.辛辛那提儿童医院医疗中心的药物遗传学实施：14年个性化医疗的经验教训。
Clin Pharmacol Ther. 2019 Jan;105(1):49-52. doi: 10.1002/cpt.1165. Epub 2018 Jul 29.
9
What do we need to transfer pharmacogenetics findings into the clinic?我们需要什么来将药物遗传学研究结果应用于临床？
Pharmacogenomics. 2018 May;19(7):589-592. doi: 10.2217/pgs-2018-0026. Epub 2018 Apr 27.
10
Pharmacogenomics: paving the path to personalized medicine.药物基因组学：铺就个体化医学之路。
Pharmacogenomics. 2010 Feb;11(2):141-6. doi: 10.2217/pgs.09.174.
引用本文的文献
1
AI-powered precision medicine: utilizing genetic risk factor optimization to revolutionize healthcare.人工智能驱动的精准医学：利用遗传风险因素优化彻底改变医疗保健。
NAR Genom Bioinform. 2025 May 5;7(2):lqaf038. doi: 10.1093/nargab/lqaf038. eCollection 2025 Jun.
2
PSnpBind-ML: predicting the effect of binding site mutations on protein-ligand binding affinity.PSnpBind-ML：预测结合位点突变对蛋白质-配体结合亲和力的影响。
J Cheminform. 2023 Mar 2;15(1):31. doi: 10.1186/s13321-023-00701-3.
3
A p53 transcriptional signature in primary and metastatic cancers derived using machine learning.利用机器学习得出的原发性和转移性癌症中的p53转录特征。
Front Genet. 2022 Aug 29;13:987238. doi: 10.3389/fgene.2022.987238. eCollection 2022.
4
PSnpBind: a database of mutated binding site protein-ligand complexes constructed using a multithreaded virtual screening workflow.PSnpBind：一个使用多线程虚拟筛选工作流程构建的突变结合位点蛋白质-配体复合物数据库。
J Cheminform. 2022 Feb 28;14(1):8. doi: 10.1186/s13321-021-00573-5.
5
genotype-guided antiplatelet therapy: promises and pitfalls.基因指导的抗血小板治疗：前景与陷阱。
Pharmacogenomics. 2020 Aug;21(12):889-897. doi: 10.2217/pgs-2020-0046. Epub 2020 Jul 29.
6
Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology.噻嗪类利尿剂与多民族人群QT间期的药物基因组学研究：基因组流行病学心脏与衰老研究队列
Pharmacogenomics J. 2018 Apr;18(2):215-226. doi: 10.1038/tpj.2017.10. Epub 2017 Jul 18.
7
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.临床药物基因组学实施联盟关于SLCO1B1与辛伐他汀所致肌病的指南：2014年更新版
Clin Pharmacol Ther. 2014 Oct;96(4):423-8. doi: 10.1038/clpt.2014.125. Epub 2014 Jun 11.
8
Secondary use of clinical data: the Vanderbilt approach.临床数据的二次利用：范德比尔特方法
J Biomed Inform. 2014 Dec;52:28-35. doi: 10.1016/j.jbi.2014.02.003. Epub 2014 Feb 14.
9
Biomarkers in psychosis: an approach to early identification and individualized treatment.精神病生物标志物：早期识别和个体化治疗的方法。
Biomark Med. 2014;8(1):51-7. doi: 10.2217/bmm.13.134.
10
Genetics of adverse reactions to haloperidol in a mouse diallel: a drug-placebo experiment and Bayesian causal analysis.小鼠双列杂交中氟哌啶醇不良反应的遗传学：一项药物-安慰剂实验及贝叶斯因果分析
Genetics. 2014 Jan;196(1):321-47. doi: 10.1534/genetics.113.156901. Epub 2013 Nov 15.
本文引用的文献
1
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.HLA-A*3101 与卡马西平诱导的欧洲人过敏反应。
N Engl J Med. 2011 Mar 24;364(12):1134-43. doi: 10.1056/NEJMoa1013297.
2
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.台湾的卡马西平诱导的毒性作用和 HLA-B*1502 筛查。
N Engl J Med. 2011 Mar 24;364(12):1126-33. doi: 10.1056/NEJMoa1009717.
3
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.临床药物遗传学实施联盟噻嘌呤甲基转移酶基因型和巯嘌呤剂量指南。
Clin Pharmacol Ther. 2011 Mar;89(3):387-91. doi: 10.1038/clpt.2010.320. Epub 2011 Jan 26.
4
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).华法林基因分型降低了住院率，这是 MM-WES（美科梅奥华法林有效性研究）的结果。
J Am Coll Cardiol. 2010 Jun 22;55(25):2804-12. doi: 10.1016/j.jacc.2010.03.009. Epub 2010 Apr 8.
5
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.细胞色素P450 2C19基因与氯吡格雷治疗的抗血小板作用及临床疗效的相关性
JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232.
6
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.白细胞介素28B的基因变异可预测丙型肝炎治疗诱导的病毒清除情况。
Nature. 2009 Sep 17;461(7262):399-401. doi: 10.1038/nature08309. Epub 2009 Aug 16.
7
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.HLA - B*5701基因型是氟氯西林所致药物性肝损伤的主要决定因素。
Nat Genet. 2009 Jul;41(7):816-9. doi: 10.1038/ng.379. Epub 2009 May 31.
8
Estimation of the warfarin dose with clinical and pharmacogenetic data.利用临床和药物遗传学数据估算华法林剂量。
N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329.
9
SLCO1B1 variants and statin-induced myopathy--a genomewide study.溶质载体有机阴离子转运体家族1成员B1（SLCO1B1）变异与他汀类药物诱发的肌病——一项全基因组研究
N Engl J Med. 2008 Aug 21;359(8):789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23.
Zotero 插件